Chuansheng Zheng

Prof. Dr. Chuansheng Zheng

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
FWFuquan Wang
Fuquan Wang
LZLicheng Zhu
Licheng Zhu
FXFu Xiong
Fu Xiong
BCBin Chai
Bin Chai
JWJihua Wang
Jihua Wang
CZChuansheng Zheng
Chuansheng Zheng
Objective: To explore the effect and mechanism of relaxin (RLX) in the growth and metastasis of livercancer after combination treatment with transarterial chemoembolization (TACE). Materials and methods: HCCLM3 and Huh-7 cells were adopted to evaluate the effect of tumor proliferation, migration, and invasion after RLX administration in vitro. The rabbit VX2 model was used to evaluate the biosafety, doxorubicin penetration, local tumor response, tumor metastasis, and survival benefit of RLX combined with TACE treatment. Results: RLX did not affect the proliferation, migration, or invasion of HCCLM3 and Huh-7 cells, and the expression of E-cadherin and HIF-1α also remained unchanged while the MMP-9 protein was upregulated in vitro. In the rabbit VX2 model, compared to the normal saline group (NS), RLX group (RLX) and TACE mono-therapy group (TACE), the group that received TACE combined with RLX (TACE + RLX) showed an improved local tumor response and survival benefit. Furthermore, TACE combined with RLX was found to reduce tumor metastasis. This combination therapy reduced the fibrotic extracellular matrix in the tumor microenvironment, allowing for better penetration of doxorubicin, improved infiltration of CD8+ T cells and affected the secretion of cytokines. Additionally, RLX combined with TACE was able to decrease the expression of HIF-1α and PD-L1. The biosafety of TACE combined with RLX was also confirmed. Conclusion: RLX synergized with TACE by mitigating the fibrotic extracellular matrix and tumor hypoxic microenvironment, improving the therapeutic effect and inhibiting metastasis during the treatment of liver cancer.

8 June 2026 in BMC Cancer
Verified
Journal Article
Open access
HLHaohao Lu
Haohao Lu
BLBin Liang
Bin Liang
CZChuansheng Zheng
Chuansheng Zheng
CZChuansheng Zheng
Chuansheng Zheng
XXXiangwen Xia
Xiangwen Xia
Objective: To investigate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and icaritin in the treatment of patients with unresectable hepatocellular carcinoma (uHCC) with poor physical condition, aiming to provide a safer and more effective treatment strategy for patients with advanced uHCC and poor physical status. Materials and methods: Clinical data from 49 patients with uHCC and poor physical condition who received treatment between June 2022 and December 2023 were collected. The patients were divided into two groups based on their treatment method: TACE + LEN+Icaritin group ( N = 21) and TACE group ( N = 28). The primary endpoints were the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) of the tumor in both groups. The secondary endpoint was the incidence of treatment-related adverse events (AEs) in both groups. Results: The ORR and DCR of the TACE + LEN+Icaritin group were significantly higher than those of the TACE group (66.7% vs. 28.6%, P = 0.011; 85.7% vs. 53.6%, P = 0.030). The mPFS of the TACE + LEN+Icaritin group was longer than that of the TACE group (8.6 months vs. 4.1 months, HR = 0.316, 95%CI: 0.166–0.599; P < 0.001). The incidence of hand-foot syndrome (all grades) was higher in the TACE + LEN+Icaritin group compared to the TACE group ( P = 0.004), but there was no significant difference in the incidence of grade 3/4 hand-foot syndrome between the two groups ( P = 0.429). The incidence of fatigue and anorexia (all grades) was lower in the TACE + LEN+Icaritin group compared to the TACE group ( P < 0.05). A total of 66.7% of patients in the TACE + LEN+Icaritin group showed improvement in physical condition after treatment, which was significantly higher than in the TACE group ( P = 0.022). Conclusion: TACE combined with lenvatinib and icaritin demonstrates good efficacy and safety in the treatment of patients with uHCC and poor physical condition (ECOG = 2). This combination therapy may be a viable option for improving prognosis and quality of life in patients with uHCC and poor physical condition.

8 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LYLi Yu
Li Yu
MFMengfei Fu
Mengfei Fu
LYLiu Yang
Liu Yang
YCYang Chen
Yang Chen
XCXiao Chen
Xiao Chen
HSHui Sun
Hui Sun
Objective: To explore three novel fasting blood glucose (FBG)-based novel indicators, including FBG-to-albumin ratio (FAR), FBG-to-lymphocytes ratio (FLR), and FBG-to-hemoglobin ratio (FHR), in predicting prognosis and detecting metastasis for patients with pancreatic neuroendocrine neoplasms after resection. Materials and methods: A total of 178 pNEN patients underwent surgical resection were included in this study. Receiver operating characteristic (ROC) curves were used to evaluate the diagnosis values of FAR, FLR, and FHR, and the cut-off values were obtained for further analyses. Univariate and multivariate analyses were conducted to determine the independent predictors. The Kaplan-Meier method was used to evaluate the progression-free survival (PFS) and overall survival (OS) of the pNEN patients. Results: The optimal cut-off values of FAR, FLR, and FHR were 0.17, 2.85, and 0.028, respectively. As for PFS, the area under the curve (AUC) was 0.693 for FAR, 0.690 for FLR, and 0.661 for FHR, respectively. The AUC was 0.770, 0.692, and 0.715 accordingly for OS. The groups with lower FAR, FLR, and FHR were significantly associated with prolonged PFS and OS (p < 0.05). In patients with metastasis, the lower FAR group was correlated with significantly longer PFS and OS (p = 0.022 and 0.002, respectively). The FLR was an independent predictor of PFS in pNEN patients, and the FAR was a predictor of OS. FAR was an independent indicator of PFS in patients with metastasis. Conclusion: Preoperative FAR, FLR, and FHR are effective in predicting the prognosis of pNEN patients and detecting the synchronous metastases.

24 January 2026 in ACS Omega
Verified
Journal Article
Open access
LLLi Ling
Li Ling
NCNing Chen
Ning Chen
GCGuotao Cheng
Guotao Cheng
ALAnna Liu
Anna Liu
LZLing Zhang
Ling Zhang
CZChuansheng Zheng
Chuansheng Zheng
The development of liquid embolic agents has significantly advanced the field of transcatheter arterial embolization (TAE). Conventional solid embolic agents, such as gelatin sponges or poly-(vinyl alcohol) (PVA), are limited by their lack of intrinsic radiopacity and reliance on lipiodol, necessitating a cumbersome two-step embolization process. Consequently, a critical need exists for embolic materials that combine intrinsic imaging functionality with enhanced biocompatibility to advance clinical outcomes. We have developed a novel liquid embolic material based on poly-(N-isopropylacrylamide)-co-acrylic acid nanogels (PNAs). Mixing PNAs with lipiodol using a medical three-way stopcock yields a thermosensitive lipiodol-based gel emulsion (TLGE). This material exhibits excellent temperature sensitivity and biocompatibility. Notably, the TLGE demonstrates injectable fluidity and sufficient X-ray contrast in an ex vivo decellularized liver model. This embolization technique requires only a single injection and allows for rapid mixing, offering significant practical advantages in the clinic. Digital subtraction angiography (DSA) facilitates intraoperative imaging and real-time monitoring of the embolization process, aiding in the prevention of nontarget embolization and ensuring precise treatment. In a preclinical study, following the embolization of the right renal artery in New Zealand rabbits, a 42-day observation period revealed no instances of vessel recanalization or damage to nontarget organs. Consequently, this innovative temperature-sensitive material demonstrates significant potential for clinical application in TAE procedures.